03 822.000010
`
`PATENT
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Examiner: B. Kifle
`
`Group Art Unit: 1624
`
`Confirmation No.: 6870
`
`) :
`
`) :
`
`) :
`
`)
`
`~
`
`May 13, 2008
`
`In re Patent of:
`
`DONALD J.P. PINTO ET AL.
`
`Appln. No.: 10/245,122
`
`Filed: September 17, 2002
`
`For:
`
`LACTAM-CONTAINING CO1\/[POUNDS
`AND DERIVATIVES THEREOF AS
`FACTOR XA INHIBITORS
`
`U.S. Patent No.: 6,967,208 B2
`
`Issued: November 22, 2005
`
`Commissioner for Patents
`
`P.O. Box 1450
`
`Alexandria, VA 22313-1450
`
`REQUEST FOR EXPEDITED ISSUANCE OF CERTIFICATE
`OF CORRECTION UNDER M.P.E.P. 1480.01 AND RULE 322
`
`Sir:
`
`It is respectfully requested that a Certificate of Correction be issued by the
`
`Patent and Trademark Office in an expedited manner in accordance with the attached Certificate
`
`of Correction Form PTO-1050. All errors in the printed patent for which the correction is
`
`requested are a result of Patent and Trademark Office mistakes.
`
`To expedite review, Patentees note that it appears that most of the Patent and
`
`Trademark Office errors identified in the attached Form PTO-1050 resulted from printing the
`
`claims filed on November 19, 2003, rather than the claims filed on September 22, 2004, which
`
`BIVIS 2007
`CFAD v. BIVIS
`|PR2015—01723
`
`BMS 2007
`CFAD v. BMS
`IPR2015-01723
`
`

`
`were subsequently allowed by the Examiner. Also, the printed patent does not reflect the
`
`information from (i) the petition to request correction of inventorship submitted on October 8,
`
`2004 and subsequently granted by the Office Communication of August 17, 2005; and (ii) the
`
`amendment to the specification submitted on September 16, 2004 and subsequently entered by the
`
`Examiner.
`
`In support of this expedited request, as required by M.P.E.P. 1480.01,
`
`Patentees submit herewith copies of the following documents:
`
`1.
`
`2.
`2.
`3
`
`4.
`
`5.
`
`Amendment filed November 19, 2003
`
`Amendment filed September 16, 2004
`Amendment filed September 22, 2004
`Petition and Fee Deleting Correctly Named Persons Who are Not
`Inventors of Invention Now Being Claimed (Under 37 C.F.R. § 1.48(b))
`filed October 8, 2004
`
`Notice of Allowance mailed October 13, 2004
`
`Office Communication confirming deletion of inventors mailed August
`17, 2005.
`
`Patentees’ undersigned attorney may be reached in our New York office by
`
`telephone at (212) 218-2100. All correspondence should continue to be directed to our address
`
`given below.
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`
`New York, New York 10112-3801
`
`Facsimile:
`
`(212) 218-2200
`
`Respectfully submitted,
`
`/Jason M. Okun/
`
`Jason M. Okun
`
`Attorney for Patentees
`Registration No. 48,512
`
`Page 2
`
`Page 2
`
`

`
`Staple
`Here
`Only!
`
`
`
`PR|NTER'STRIMLINE
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`US 6,967,208 B2
`
`DATED
`
`November 22, 2005
`
`|NVENTOR(S)
`
`DONALD J. P. PINTO ET AL.
`
`Page 1 of 17
`
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`ON THE TITLE PAGE |75 |:
`
`Inventors, “Yun-Long Li, Wilmington DE (US); Wei Han, Yardley, PA (US);”
`should be deleted.
`
`COLU1\/1N 174:
`
`Line 24, “piperidinyl)phenyl-4,5,6,7-tetrahydro-1H-pyrazole- ” should read
`--piperidinyl)phenyl] -4, 5 , 6, 7-tetrahydro-1H- --;
`Line 25, “[3,4-c]pyridine-3-caboxamide” should read --pyrazolo[3,4-c]pyridine-3-
`caboxamide--;
`
`Line 47, “CDCI3” should read --CHCI3--; and
`Line 49, “CDCI3” should read --CHCI3--.
`
`COLU1\/1N 175:
`
`Line 29, “1-(4-meyhoXyphenyl)- ” should read --1-(4-methoXyphenyl)- --.
`
`COLU1\/[N 237:
`
`Lines 15-20, “
`
`N—r\/I4
`
`\
`
`” should read --ring M, including P1, P2,
`
`MAILING ADDRESS OF SENDER:
`
`
`PATENT N0. US 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCTNTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`
`Form PTO 1050 (Rev. 3-82)
`
`page 3
`
`N0 °"add"- “Pies
`@ 30¢ pe’ page
`
`:> E
`
`Page 3
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`£0
`E
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 2 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`M1, and M2, is substituted with 0-2R” and is
`
`Lines 22-23, “ring M, including P1, P2, and M1, and M2 is substituted with 0-2 R1“
`and is” should be deleted;
`
`R18
`
`Lines 25-30, “
`
`” should read --ring P, including P1, P2, and P3,
`
`P4
`
`Line 33, “ring P, including P1, P2, and P3, is” should be deleted; and
`Line 34, “P4 is —G1 —G;” should read --M4 is —A —B;
`P4 is —G1 —G;--.
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 4
`
`_
`N0 °‘'add''- 009'“
`@ 30¢ Wage
`
`:5 j
`
`Page 4
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`£0
`E
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 3 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLU1\/[N 238:
`
`7
`Line 1, “S(O)P,” should read --S(O)P,--"
`Line 33, “6 4-8 membered” should read --6 membered--; and
`
`Line 34, “0-2 double bonds are” should read --0 double bond is--.
`
`COLU1\/[N 239:
`
`Line 18, “NR2°(O)NHR2,” should read --NR2C(O)NHR2,--.
`
`COLUl\/IN 241:
`
`Line 27, “(CR3R3“),1 Cl,” should read --(CR3R3*‘),1Cl,--.
`
`COLUl\/IN 242:
`
`Line 21, “6;” should read --6; and--.
`
`COLUl\/IN 243:
`
`Line 30, “CHZCHZCHZCH3,” should read --CHZCHZCHZCH3,--;
`Line 38, “CHZCHZCHZCH3,” should read --CHZCHZCHZCH3,--; and
`Line 62, “benzyl” should read --benzyl,--.
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 5
`
`_
`N0 °"add"- 009'“
`@ 30¢ image
`
`:5 j
`
`Page 5
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`£0
`E
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 4 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLU1\/[N 244:
`
`Line 10, “benzyl phenyl;” should read --benzyl, and phenyl;--; and
`Line 51, “alkyl NR3SO2CF3,” should read --alkyl, NR3SO2CF3,--.
`
`COLUl\/[N 246:
`
`Lines20-30,“<5 ”shouldread--
`
`--.
`
`CH3NH2
`
`CH2NH2
`
`COLUl\/[N 248:
`
`NH2
`
`NH2
`
`Lines 1-5, “ N /
`I
`O \
`
`” should read -- N /
`I
`O
`
`NH2
`
`NH2
`
`Lines 10-15, “ N /
`I
`O \
`
`” should read -- N /
`I
`O
`
`NH2
`
`NH2
`
`Lines35-40,“ ” shouldread -- --.
`
`\
`
`CH3NH2
`
`\
`
`CH2NH2
`
`MAILING ADDRESS OF SENDER:
`
`
`PATENT N0. US 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 5
`
`_
`N0 °"add"- 009'“
`@ 30¢ pe’ Page
`
`:5 j
`
`Page 6
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`50
`g
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 5 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLUl\/IN 249:
`
`“W
`Lines 5-10, “ \
`
`NH2
`
`Lines 15-20, “
`
`/
`Lines 25-30, “N
`
`\
`
`i
`
`N
`Line 35, “ / I
`\
`
`N
`
`\
`/
`
`CI
`
`Line65, 1,
`
`CHZNH2” should read --
`
`00
`
`NH2
`
`” should read --
`
`/
`” should read --N
`
`\
`
`‘
`
`SO2NH2
`
`so2cH3
`
`CHZNHZ --;
`
`--;
`
`--;
`
`SO2NH2
`
`SOZNH2
`
`” should read --
`
`H
`N
`
`N
`
`\
`/
`
`‘
`
`CI
`
`--; and
`
`» Shouldread——
`
`SO2Ch3
`
`SO2CH3
`
`COLUl\/IN 251:
`
`Lines 15-20, “
`
`H
`N
`1 \ \ ” should read --
`N /
`
`H
`N
`
`1 \
`N / /
`
`--;
`
`MAILING ADDRESS OF SENDER:
`
`
`PATENT N0. US 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 7
`
`N0 °"add"- “Pies
`@ 30¢ pe’ page
`
`:> j
`
`Page 7
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`50
`g
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 6 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`” should read --
`
`\
`
`N
`
`H
`
`\ N
`‘
`/
`/ N
`
`N
`
`--; and
`
`H N
`
`‘N” should read --\ --.
`
`/
`
`N
`
`NH2
`
`NH2
`
`.
`Lrnes 20-25, “
`
`Lines 25-30, “
`
`COLUl\/[N 252:
`
`Thefirstrowshouldread--
`
`</N
`
`N
`H
`
`0
`
`I \N F<\ --; and
`
`/
`
`/
`
`H
`N
`.
`Lrne 35, “ /
`
`NH2
`
`\ N
`
`/
`
`” should read --
`
`H
`N
`
`\
`
`NH
`
`2
`\ N
`
`/
`
`--.
`
`I
`
`COLUl\/[N 253:
`
`Line 41, “1-4 hetero ” should read --1-4 hetero- --.
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 8
`
`N0 °"add"- “Pies
`@ 30¢ image
`
`:> j
`
`Page 8
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`50
`g
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 7 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLU1\/[N 254:
`
`Line 3, “R4” should read --R4“,--; and
`Line 24, “C(O)R°” should read --C(O)R2°--.
`
`COLU1\/[N 255:
`
`Lines15-20,“é ”shouldread--gl --;and
`
`N
`
`\
`2NH
`
`NH2
`
`\
`
`N
`NH2
`
`NH2
`
`Line 65, “ N /
`I
`
`O \
`
`” should read -- N /
`I
`
`--.
`
`O
`
`COLUl\/[N 256:
`
`NH2
`
`--; and
`
`” should read -- N /
`
`I O
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 9
`
`N0 °"add"- “Pies
`@ 30¢ image
`
`:> j
`
`Page 9
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`50
`g
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 8 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`HQN
`
`NH2
`
`Line15,“ ”shouldread-- --;
`
`\
`
`F
`
`\
`
`F
`
`HZN
`
`NH2
`
`Lines 20-25, “N /
`
`” should read --N /
`
`\
`
`H
`N
`
`” should read --
`
`\
`
`H
`N
`
`/
`
`\
`
`NH2
`
`COLUl\/[N 258:
`
`Line5,“ /”shouldbedeleted;and
`
`HN
`
`CC
`
`'
`Lrne 25,
`
`H
`
`77
`\ N should read --
`
`H
`
`/ N --.
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 10
`
`N0 °"add"- “Pies
`@ 30¢ image
`
`:> j
`
`Page 10
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`£0
`E
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 9 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLU1\/IN 2591
`
`Line 67, “CH2c(O)R2",” should be deleted.
`
`COLU1\/[N 261:
`
`Line 50-55, “
`
`N /
`
`\
`
`” should read --
`
`/N
`
`\
`
`--.
`
`COLU1\/[N 262:
`
`Line 34, “and is” should read --and is:--;
`
`Line 35, “selected from the group:” should be deleted;
`
`O
`
`O
`
`\
`
`Lines 37-42, “\N/H\ Mk ” should read --
`@ Q
`
`jR4a
`
`jR4a
`
`0
`
`O
`
`\N
`
`Lines 43-53, “
`
`?R4a \NJR
`V ” should be deleted.
`
`RI
`
`R4a
`
`/
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 11
`
`_
`N0 01 add''- 009'“
`@ 30¢ ‘Wage
`
`:5 j
`
`Page 11
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`£0
`E
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 10 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLU1\/[N 263:
`
`Line 38, “S(O)p-phenyl” should read --S(O)2-phenyl--; and
`Line 43, “SO2NR2R2a.” should read --SOZNRZRZ“.--.
`
`COLU1\/[N 265:
`
`Lines20-25,“
`
`U 0
`[S5
`
`\
`
`1
`
`F
`
`0
`
`N
`
`S5”shouldbedeleted;
`
`\
`
`Line 30, “is selected from:” should read --is--;
`
` \ 0
`N
`
`\
`
`Line 35, “
`
`‘ ” should be deleted; and
`
`Line 66, “phenyl-4,5,6,7-tetrahydro-1H-pyrazole-[3,4-c]” should read
`--phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo-[3,4-c]--.
`
`COLU1\/[N 266:
`
`Lines 21-23 , “1-(4-methoXyphenyl)-7-oXo-6-[4-(2-oXo-1(2H)-pyridinyl)phenyl]-
`4, 5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3 -carboxamidef’
`should be deleted;
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 12
`
`_
`N0 01 add''- 009'“
`@ 30¢ image
`
`:5 j
`
`Page 12
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`50
`g
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 11 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`Lines 27-29, “1-(4-methoXyphenyl)-6-(4-(2-oXo-1(2H)-pyridinyl)phenyl]-3 -
`(2-pyridinyl)-1,4, 5 , 6-tetrahydro-7H-pyrazolo [3 ,4-c]pyridin-7-one;”
`should be deleted;
`
`Lines 40-42, “1-(3 -chlorophenyl)-7-oXo-6-[4-(2-oXo-1(2H)pyridinyl)phenyl]-
`4, 5,6,7-tetrahydro- lH-pyrazolo[3 ,4-c]pyridine-3 -carboxamide;”
`should be deleted;
`
`Lines 49-5 1, “1-(4-methoXyphenyl)-7-oXo-6-[4-(2-oXo-1(2H)-pyridinyl)phenyl]-
`4, 5,6,7-tetra hydro-1H-pyrazolo[3 ,4-c]pyridine-3 -carbonitrile;”
`should be deleted;
`
`Lines 5 8-60, “1-(2,3 -dihydro-1H-indol-6-yl)-6-[4-(2-oXo-1(2H)-
`pyridinyl)phenyl] -3 -(trifluoromethyl)-1,4, 5 , 6-tetrahydro-7H-
`pyrazolo[3 ,4-c]pyridin-7-one;” should be deleted; and
`Lines 65-67, “1-(2,3 -dihydro-1H-isoindol-5-yl)-6-[4-(2-oXo-2H-pyridin-
`1 -yl)phenyl] -3 -trifluoromethyl-1,4, 5 , 6-tetrahydropyrazolo [3 ,4-
`c]pyridin-7-one;” should be deleted.
`
`COLU1\/[N 267:
`
`Lines 4- 1 5 ,
`
`“ethyl 1-(4-methoxyphenyl)-7-oXo-6-[4-(2-oXo-1(2H)-pyridinyl)
`phenyl] -4, 5 , 6, 7-tetrahydro- 1H-pyrazolo [3 ,4-c]pyridine-
`3 -carboxylate; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1(2H)-
`pyridinyl)phenyl] -4, 5 , 6, 7-tetrahydro- 1H-pyrazolo [3 ,4-c]
`pyridine-3-carboxylic acid; 1-(4-methoxyphenyl)-N,N-dimethyl-
`7-oXo-6-[4-(2-oXo-1(2H)-pyridinyl)phenyl]-4, 5 , 6, 7-
`tetrahydro- 1H-pyrazolo [3 ,4-c]pyridine-3 -carboxamide;
`N-({ 1-(4-methoxyphenyl)-7-oXo-6-[4-(2-oXo-1(2H)-pyridinyl)
`phenyl] -4, 5 , 6, 7-tetrahydro- 1H-pyrazolo [3 ,4-c]pyridin-3 -yl}
`carbonyl)methanesulfonamide;” should be deleted;
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 13
`
`N0 °"add"- “Pies
`@ 30¢ image
`
`:> j
`
`Page 13
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`Staple
`Here
`Only!
`
`
`
`PR|NTER'STRIMLINE
`
`PATENT N0.
`
`US 6,967,208 B2
`
`DATED
`
`November 22, 2005
`
`|NVENTOR(S)
`
`DONALD J. P. PINTO ET AL.
`
`Page 12 of 17
`
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`Lines 19-25 , “1-(4-methoXyphenyl)-6-[4-(2-oXo-1(2H)-pyridinyl)phenyl]-3 -
`(1H-tetraazol-5-yl)-1,4, 5,6,-tetrahydro-7H-pyrazolo[3 ,4-
`c]pyridin-7-one;3 -{4-[dimethylamino)methyl]-1,3 -oXazol-2-yl}-
`1-(4-methoXyphenyl)-6-[4-(2-oXo-1(2H)-pyridinyl)phenyl]-
`1,4, 5,6,-tetrahydro-7H-pyrazolo[3 ,4-c]pyridin-7-one,”
`should be deleted;
`
`Lines 3 2-40, “1-(4-methoxy-phenyl)-3 -(4-methyl-oXazol-2-yl)-6-
`[4-(2-oXo-2H-1-pyridin-1-yl)-phenyl]-1,4, 5 , 6-tetrahydro-pyrazolo
`[3 ,4-c]pyridin-7-one; 3 -acetyl-1-(4-methoXy-phenyl)-6-[4-(2-oXo-
`2H-pyridin-1-yl)-phenyl]-1,4, 5 , 6-tetrahydro-pyrazolo [3 ,4-c]
`pyridin-7-one; 3 -(4, 5 -dihydro-1H-imidazol-2-yl)-1-(4-methoXy-
`phenyl)-6-[4-(2-oXo-2H-pyridin-1-yl)-phenyl]-1,4, 5 , 6-
`tetrahydro-pyrazolo[3 ,4-c]pyridin-7-one,” should be deleted;
`Lines 5 1-5 3 , “3 -hydroXymethyl-1-(4-methoXy-phenyl)-6-[4-(2-oXo-
`2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-
`pyrazolo[3 ,4-c]pyridin-7-one,” should be deleted;
`Lines 5 7-5 9, “3 -( 1 -hydroXy- 1 -methyl-ethyl)- 1 -(4-methoXy-phenyl)-6- [4-
`(2-oXo-2H-pyridin-1-yl)-phenyl]-1,4, 5 , 6-tetrahydro-pyrazolo
`[3 ,4-c]pyridin-7-one,” should be deleted;
`Line 61, “(2-oXopiperidin-1-yl)phenyl]-4, 5,6,7-tetrahydro-1H- ” should read --(2-
`oXo-piperidin-1-yl)phenyl]-4, 5 , 6, 7-tetrahydro-1H- --; and
`Lines 65-67, “2-dimethylamino-N-{ 1-(4-methoxyphenyl)-7-oXo-6-[4-(2-oXo-
`2H-pyridin-1-yl)-phenyl]-4, 5 ,6, 7-tetrahydro- 1H-pyrazolo [3 ,4-c]
`pyridin-3 -ylmethyl } acetamidef’ should be deleted.
`
`MAILING ADDRESS OF SENDER:
`
`
`PATENT N0. US 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`
`Form PTO 1050 (Rev. 3-82)
`
`page 14
`
`_
`N0 °"add"- °°P'e3
`@ 30¢ P6’ page
`
`:> R
`
`Page 14
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`Staple
`Here
`Only!
`
`
`
`PR|NTER'STRIMLINE
`
`PATENT N0.
`
`US 6,967,208 B2
`
`DATED
`
`November 22, 2005
`
`|NVENTOR(S)
`
`DONALD J. P. PINTO ET AL.
`
`Page 13 of 17
`
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLU1\/[N 268:
`
`Line 1, “N-{ 1-(4-methoXyphenyl)-7-oXo-6-[4-(2-oXopiperidin-1- ” should read
`--N-{ 1-(4-methoxyphenyl)-7-oXo-6-[4-(2-oXo-piperidin-1- --;
`Line 4, “N-{ 1-(4-methoXyphenyl)-7-oXo-6-[4-(2-oXopiperidin-1- ” should read
`--N-{ 1-(4-methoxyphenyl)-7-oXo-6-[4-(2-oXo-piperidin-1- --;
`Lines 7- 12, “N-hydroxy-3 -{7-oXo-6-[4-(2-oXo-2H-pyridin-1-yl)-phenyl]-3 -
`trifluoromethyl-4, 5,6,7-tetrahydro-pyrazolo[3 ,4-c]
`pyr1din-1-yl}-benzamidine; N-methoxy-3 - { 7-oXo-6- [4-
`(2-oXo-2H-pyridin-1-yl)-phenyl]-3 -trifluoromethyl-4, 5 ,6, 7-
`tetrahydro-pyrazolo [3 ,4-c]pyridin-1-yl}-benzamidinef’
`should be deleted;
`
`Line 14, “piperidinyl)phenyl]-4,5,6,7-tetrahydro-pyrazolo[3 ,4-c]” should read
`--piperidinyl)phenyl] -4, 5 , 6, 7-tetrahydro- 1H-pyrazolo [3 ,4-c] --;
`Lines 22-27, “2-{7-oXo-6-[4-(2-oXo-2H-pyridin-1-yl)-phenyl]-3 -
`trifluoromethyl-4, 5 , 6, 7-tetrahydro-pyrazolo [3 ,4-c]pyridin-
`1-yl}-benzenesulfonamide; N-acetyl-2- { 7-oxo-6-[4-(2-oxo-
`2H-pyridin-1-yl)-phenyl]-3 -trifluoromethyl-4, 5 , 6, 7-
`tetrahydro-pyrazolo [3 ,4-c]pyridin- 1 -yl } -benzenesulfonamidef’
`should be deleted;
`
`Line 3 O, “4-c]pyridin-7-one; should read --4-c]pyridin-7-one; and--;
`Lines 3 1-3 3 , “1-(3 -chloro-phenyl)-3 -methanesulfonyl-6- [4-(2-oXo-2H-
`pyr1din-1-yl)-phenyl]- 1,4, 5 , 6-tetrahydro-pyrazolo [3 ,4-c]
`pyridin-7-one,” should be deleted;
`Line 3 6, “and,” should be deleted; and
`
`Lines 3 7-3 9, “3 -{7-oXo-6-[4-(2-oXo-2H-pyridin-1-yl)-phenyl]-3 -trifluoromethyl-
`4, 5,6, 7-tetrahydro-pyrazolo [3 ,4-c]pyridin-1-yl}-benzamidef’
`should be deleted.
`
`MAILING ADDRESS OF SENDER:
`
`
`PATENT N0. US 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`
`Form PTO 1050 (Rev. 3-82)
`
`page 15
`
`N0 °"add"- “Pies
`@ 30¢ pe’ page
`
`:> E
`
`Page 15
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`£0
`E
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 14 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLU1\/IN 269:
`
`Line 4, “phenyl-4,5,6,7-tetrahydro-1H-pyrazole-[3,4-c]” should read
`--phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]--.
`Lines 7-12, claim 14 should be deleted; and
`
`Lines 25-43, claims 17 to 19 should be deleted.
`
`COLU1\/IN 270:
`
`Lines 9-12, claim 28 should be deleted; and
`
`Lines 21-32, claims 31 to 33 should be deleted.
`
`COLU1\/IN 273:
`
`Lines 16-45, claims 62 to 68 should be deleted.
`
`COLU1\/IN 274:
`
`Line 23, “arterial, embolism,” should read --arterial embolism,--;
`
`Lines 38-67, claims 83 to 89 should be deleted.
`
`COLU1\/[NS 275-276 :
`
`Lines 1-32 and 1-30, respectively, claims 90 to 103 should be deleted.
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 16
`
`_
`N0 °‘'add''- 009'“
`@ 30¢ ‘Wage
`
`:5 j
`
`Page 16
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`Staple
`Here
`Only!
`
`
`
`PR|NTER'STRIMLINE
`
`PATENT N0.
`
`US 6,967,208 B2
`
`DATED
`
`November 22, 2005
`
`|NVENTOR(S)
`
`DONALD J. P. PINTO ET AL.
`
`Page 15 of 17
`
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`COLU1\/[N 276:
`
`Line 31, add claims 104 to 118 as follows:
`
`--104. A compound according to claim 13 is a crystalline compound.
`
`105. A pharmaceutical composition, comprising: a pharmaceutically
`acceptable carrier and a therapeutically effective amount of a compound of claim
`1 O4.
`
`106. A method for treating a thromboembolic disorder, comprising:
`administering to a patient in need thereof a therapeutically effective amount of a
`compound of claim 104.
`
`107. A method according to claim 106, wherein the thromboembolic
`disorder is selected from the group consisting of arterial cardiovascular
`thromboembolic disorders, venous cardiovascular thromboembolic disorders, and
`thromboembolic disorders in the chambers of the heart.
`
`108. A method according to claim 106, wherein the thromboembolic
`disorder is selected from unstable angina, an acute coronary syndrome, first
`myocardial infarction, recurrent myocardial infarction, ischemic sudden death,
`transient ischemic attack, stroke, atherosclerosis, peripheral occlusive arterial
`disease, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial
`embolism, coronary arterial thrombosis, cerebral arterial thrombosis, cerebral
`embolism, kidney embolism, pulmonary embolism, and thrombosis resulting from
`(a) prosthetic valves or other implants, (b) indwelling catheters, (c) stents,
`(d) cardiopulmonary bypass, (e) hemodialysis, or (f) other procedures in which
`blood is exposed to an artificial surface that promotes thrombosis.
`
`MAILING ADDRESS OF SENDER:
`
`
`PATENT N0. US 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`
`Form PTO 1050 (Rev. 3-82)
`
`page 17
`
`N0 °"add"- “Pies
`@ 30¢ pe’ page
`
`:> E
`
`Page 17
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`50
`g
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 16 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`109. A method according to claim 108, wherein the thromboembolic
`disorder is an acute coronary syndrome.
`
`110. A method according to claim 108, wherein the thromboembolic
`disorder is stroke.
`
`111. A method according to claim 108, wherein the thromboembolic
`disorder is deep Vein thrombosis.
`
`112. A method according to claim 108, wherein the thromboembolic
`disorder is pulmonary embolism.
`
`113. A process for the preparation of the crystalline compound according
`to claim 104, comprising recrystallization from isopropyl alcohol or
`CH2Cl2/EtOAc.
`
`114. A process for the preparation of the crystalline compound according
`to claim 104, comprising recrystallization from isopropyl alcohol.
`
`115. A process for the preparation of the crystalline compound according
`to claim 104, comprising recrystallization from CH2Cl2/EtOAc.
`
`116. A compound according to claim 104 is prepared by a process
`comprising recrystallization from isopropyl alcohol or CHZCIZ/EtOAc.
`
`117. A compound according to claim 104 is prepared by a process
`comprising recrystallization from isopropyl alcohol.
`
`118. A compound according to claim 104 is prepared by a process
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT N0. Us 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 18
`
`N0 01 add"- “P193
`@ 30¢ image
`
`:> j
`
`Page 18
`
`

`
`LIJ
`
`Staple
`E
`Here
`Only! 2
`E
`50
`g
`E
`D.
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT N0.
`
`DATED
`
`:
`
`:
`
`US 6,967,208 B2
`
`November 22, 2005
`
`Page 17 of 17
`DONALD J. P. PINTO ET AL.
`:
`|NVENTOR(S)
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby
`corrected as shown below:
`
`comprising recrystallization from CH2Cl2/EtOAc.--.
`
`MAILING ADDRESS or SENDER:
`
`
`PATENT No. US 6 967 208 B2
`
`FITZPATRICK, CELLA, HARPER & SCINTO
`30 Rockefeller Plaza
`New York, New York 10112-3801
`(212) 218-2100 - Telephone
`(212) 218-2200 - Facsimile
`Form PTO 1050 (Rev. 3-82)
`
`page 19
`
`N0 °"add"- “P193
`@ 30¢ image
`
`:> j
`
`Page 19
`
`

`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Pnlcnt and Trademark Office
`Addxss: COMMISSIONER FOR PATENTS
`P.0. Box I450
`Alexandria. Virginia 22313-1450
`www.uspuxgov
`
`V
`
`09/17/2002
`°W°°5
`
`10/245,122
`759°
`23°”
`STEPHEN B. DAVIS
`BRISTOL-MYERS SQUIBB COMPANY
`PATENT DEPARTMENT
`P 0 BOX 4000
`PRINCETON, NJ 085434000
`
`Donald LP. Pinto
`
`PH-7398
`
`6370
`
`_
`
`.
`
`’
`
`KIFLE, Iskucx
`
`'
`
`1524
`DATE MAILED: 08/17/2005
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`PTO-90C (Rev. 10/03)
`
`Page 20
`
`Page 20
`
`

`
`
`
`UNITED STATES DEPARTMENT OF COM1\'IERCE
`U.S. Patent and Trademark Office
`Add&: CDMMISSIONER FOR PATENTS
`P.O. Box1450
`Alexandria, Virginia 22313-1450
`
`APPLICATION N0.!
`CONTROL N0.
`
`FILING DATE
`
`FIRST NAMED INVENTORI
`PATENT IN REEXAMINATION
`
`ATTORNEY DOCKET NO.
`
`ART UNIT
`
`'
`
`PAPER
`
`20050816
`
`DATE MAILED:
`
`Please find below andlor attached an Office communication concerning this application or
`proceeding.
`«
`
`In view of the papers filed 10/08/04, the inventorship in this nonprovisional application has been changed by the. deletion of Wei Han
`and Yun-Long Li.
`
`The application will be forwarded to the Office of Initial Patent Examination (OEPE) for issuance of a corrected filing receipt, and
`correction of Office records to reflect the inventorship as corrected.
`
`Commissioner for Patents
`
`5%
`
`.
`Bruck Kifle, Ph.
`Primary Examiner
`Art Unit: 1624
`
`PTO-90C (Rev.O4-03)
`
`Page 21
`
`Page 21
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`IV:
`
`UNITED STATES DEPARTMENT (IF ('()I\’IMER(‘|<'
`United States Patent and Trademark om“
`Address: COMMISSIONER FOR PA'I'I1NIS
`P.0 Box I450
`AlI:7.aiulim, Virginia 223 I 34 450
`WWW USDIO ZUV
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`BRISTOLMYERS SQUIBB COMPANY
`PATENT DEPARTMENT
`PO. BOX 4000
`PRINCETON, NJ 08543-4000
`
`KIFLE,BRUCK
`
`1624
`DATE MAILED: I0/I 3/2004
`
`APPI.lC/\Tl()N N0.
`FILING DATE
`FIRST NAMED INVENTOR
`ATTORNEY DOCKET NO.
`CONFIRMATION N()
`
`I0/245,122
`O9/I 7/200?.
`Donald .I.P. Pinto
`PI-I-7398
`6870
`TITLE OF INVENTION. LAC‘TAM~CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
`
`
`
`APPLV TYPE
`
`nonprovisional
`
`
`
`NO
`
`340
`
`$0
`
`$40
`
`
`
`DATF. DLF,
`
`0 III 3/2005
`
`
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`BRQSELIHJQN Q11 IRE MERIIS IS CLQSEI2. THIS NOTICE OF ALLOWANCE Is NOT A GRANT OF PATENT RIGIITS.
`THIS APPLICATION is SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID VVITHIN THREE MflNTfl§ FROM THE
`MAILING DATE OF TIIIS NOTICE OR THIS APPLICATION SIIALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY [E3152]; §Am1(n BE EXIENILED.
`SEE 35 USC. 151. THE ISSUE FEE DUE INDICATED ABOVE
`REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR
`AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL
`BE REGARDED AS ABANDONED.
`
`HOW TO REPLY TO THIS NOTICE:
`
`I. Review the SMALL ENTITY status shown above.
`
`If the SMALL ENTITY is shown as YES, verify your current
`SMALL ENTITY status:
`
`If the SMALL ENTITY is shown as NO:
`
`A. If the status is the same, pay the TOTAL FEE(S) DUE shown
`above.
`
`A. Pay TOTAL FEE(S) DUE shown above, or
`
`B. If the status above is to be removed, check box 5b on Part B -
`Fee(s) Transmittal and pay the PUBLICATION FEE (if required)
`and twice the amount of the ISSUE FEE shown above, or
`
`B. If applicant claimed SMALL ENTITY status before. or is now
`claiming SMALL ENTITY status, check box 5a on Part B - Fee(s)
`Transmittal and pay the PUBLICATION FEE (if required) and 1/2
`the ISSUE FEE shown above.
`
`11. PART B - FEEI S) TRANSMITTAL should be completed and rctumed to the United States Patent and Trademark Office (USPTO) with
`your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be
`completed and returned, If you are charging the fcc(s) to your deposit account, section "4b" of Part B - Fcc(s) Transmittal should be
`completed and an extra copy of the form should be submitted.
`
`III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE FEE unless advised to the contrary.
`
`IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of
`maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`PTOL-85 (Rev. 09/04:) Approved for use through 04/30/2007.
`
`Page I of 4
`
`Page 22
`
`Page 22
`
`

`
`
`
`PART B - FEE(S) TRANSIVIITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mai Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or in (703) 746-4000
`INSTRUCTIONS: This form should he used for transmitting the ISSUF. FEE and PIJBLICATION FEE (it rcqiiircd), Blocks I
`through 5 should be completed where
`a
`rupriate. All further correspondence including the Patent, advance orders and notification of maintcnancc fees will be mziiled to the current coircs onileticc address as
`in icatcd unless corrected below or directed otherwise in Block I, by (a) specifying a new correspondence address: andlor (b) indicating a separate " EE ADDRESS” for
`maintenance fee notifications.
`
`(‘I‘RRFNT(‘0RRFSP(iNDFN('F ADDRFSS(Nnti:
`
`ll.L- Rlockl l'iir;inyt~li;ingt- afaddressl
`
`24343
`
`":90
`
`to/13/Z004
`
`BRISTOL-MYERS SQUIBB COMPANY
`.
`,
`PATENT DEPARTMENT
`P.O. BOX 4000
`
`v
`
`can only be used for domcmic mamngfi of mc
`Note. A “unit-Wale flf mum”
`Fcc( s) Transmittal. This eerti icate cannot be used for any other accompanying
`ave its own ccriificiiic of mailing or transmission.
`papers. Each additional paper, such as an assignment or formal drawing. must
`
`Certificate of Mailing or Transmission
`‘th th U ‘I cl
`I hcreb c‘rtif' that th s Fcc s Trans
`’ttal 's hci
`d
`‘t d
`States nsial LCIVICC wiilh siii icicm prgdtagel for finrgt celggsslrriairiii an ccnvenlbgc
`addressed to the Mail Sto
`ISSUE FEE address above, or being facsimile
`transmitted to the IXSPTO ( 03) 746-4000, on the date indicated below.
`
`
`
`(Signature)
`(Date)
`
`APPl,lC‘ATlO.\’ NU
`FILING DATE
`FIRST NAMED INVENTOR
`ATTORNEY DOCKET NO.
`CONFIRMATION NO.
` I0/245,l22 ()9/17/2002 Donald .l,P. Pinto Pll-7398 6870
`
`
`
`
`TITLE UF INVE.\ll‘l0N: LAC'I‘AM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INIIIBITORS
`
`APPLN. TYPI:
`SMALL ENTITY
`
`.\‘O
`l‘lOl'lpl’0VlS |0l'|3l
`
`.
`
`EXAMINER
`
`KIFLE, BRUCK
`
`ISSUE FEE
`$40
`
`ART UNIT
`
`I624
`
`PUBLICATIOIN Fl:'E
`50
`
`CLASS-SUIJCLASS
`
`SM-212080
`
`TOTAL l‘EE('S) DUE
`S40
`
`DATE DUE
`
`01/I3/2005
`
`2. For printing on the patent from pzigc, list
`1. Chan c ofcorrcspondcnee address or indication of "Fee Address" (37
`(1) the names of up to 3 rcgistcrcd patcm utlomcys
`(TR 1' 63)‘
`or agents OR, alternatively.
`:l Chan e otcorres ondcncc address (or Change of Correspondence
`(3) the namc of-a singic firm (having as 3 mcmbc, 3 2 %
`Addlc-53 0”" PTO/»
`/I 27-) 5m3‘3I‘Cd-
`|’¢8iS!°|‘°d ?m01TlC)’ 01’